AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
15 Août 2022 - 10:05PM
Business Wire
AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the
“Company”), an immuno-pharma company focused on the research and
development of therapeutics to treat multiple types of cancers,
immune disorders, and viral diseases, today issued the following
statement regarding the outcome of a hearing in the Delaware Court
of Chancery concerning a motion for a temporary restraining order
(“TRO”) sought by activist shareholder Jonathan Jorgl:
“This morning we announced in a Form 10-Q filing that on August
12, 2022, a hearing was held in the Delaware Court of Chancery
concerning a motion for a temporary restraining order sought by Mr.
Jorgl related to his nomination of director candidates for election
to the Board at our 2022 Annual Meeting of Stockholders (the
“Annual Meeting”). The Court of Chancery reconvened the hearing
today and denied Mr. Jorgl’s motion for a TRO. The Court scheduled
a hearing on Mr. Jorgl’s motion for a preliminary injunction to be
held on October 5, 2022.
We will continue to take steps to protect the rights of all
shareholders and will provide further updates as available.”
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the
research and development of therapeutics to treat multiple types of
cancers, immune disorders, and viral diseases, including COVID-19.
The Company’s lead product, Ampligen® (rintatolimod) is an
immuno-modulator with broad spectrum activity being developed for
globally important cancers, viral diseases and disorders of the
immune system.
Ampligen is currently being used to treat pancreatic cancer
patients in an Early Access Program (EAP) approved by the
Inspectorate of Healthcare in the Netherlands at Erasmus Medical
Center and AIM plans to initiate a Phase 2 clinical study in 2022.
The Company also has multiple ongoing clinical trials to evaluate
Ampligen as a combinational therapy for the treatment of a variety
of solid tumor types both underway and planned at major cancer
research centers. Additionally, Ampligen is approved in Argentina
for the treatment of severe chronic fatigue syndrome (CFS) and is
currently being evaluated in many aspects of SARS-CoV-2/COVID-19
treatments and COVID-19 Long Hauler treatment.
For more information, please visit aimimmuno.com and connect
with the Company on Twitter, LinkedIn, and Facebook.
Forward-Looking
Statements
This press release contains certain forward-looking statements
that involve risks, uncertainties and assumptions that are
difficult to predict. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as
words such as “believes,” “hopes,” “intends,” “estimates,”
“expects,” “projects,” “plans,” “anticipates” and variations
thereof, or the use of future tense, identify forward-looking
statements, but their absence does not mean that a statement is not
forward-looking. The Company’s forward-looking statements are not
guarantees of performance, and actual results could vary materially
from those contained in or expressed by such statements due to
risks, uncertainties and other factors. The Company urges investors
to consider specifically the various risk factors identified in its
most recent Form 10-K, and any risk factors or cautionary
statements included in any subsequent Form 10-Q or Form 8-K, filed
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Except as required
by law, the Company does not undertake any responsibility to update
any forward-looking statements to take into account events or
circumstances that occur after the date of this press release.
Important Information
The Company intends to file with the SEC a proxy statement and
associated WHITE proxy card in connection with the
solicitation of proxies for the Company’s Annual Meeting. Details
concerning the nominees of the Company’s Board of Directors for
election at the Annual Meeting will be included in the proxy
statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND
STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT
DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE
COMPANY’S PROXY STATEMENT AND ANY AMENDMENTS OR SUPPLEMENTS
THERETO, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION.
Investors and stockholders will be able to obtain a copy of the
proxy statement, any amendments or supplements thereto and other
documents filed by the Company free of charge from the SEC’s
website, www.sec.gov. Copies of these materials will also be
available free of charge on AIM’s Investor Relations website at
https://aimimmuno.com/sec-filings/.
Participants in the
Solicitation
The Company, its directors and certain of its executive officers
will be participants in the solicitation of proxies from
stockholders in respect of the Annual Meeting. Information
regarding the names of the Company’s directors and executive
officers and their respective interests in the Company by security
holdings or otherwise is set forth in the Company’s Annual Report
on Form 10-K for the fiscal year ended December 31, 2021, filed
with the SEC on March 31, 2022. To the extent holdings of such
participants in the Company’s securities have changed since the
amounts described in Form 10-K for the year ended December 31,
2021, such changes have been reflected on Initial Statements of
Beneficial Ownership on Form 3 or Statements of Change in Ownership
on Form 4 filed with the SEC. These documents can be obtained free
of charge from the sources indicated above. Additional information
regarding the identity of these participants in any proxy
solicitation and a description of their direct and indirect
interests, by security holdings or otherwise, will also be included
in any proxy statement and other relevant materials to be filed
with the SEC, if and when they become available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220815005647/en/
JTC Team, LLC Jenene Thomas 833-475-8247 AIM@jtcir.com OR
Longacre Square Partners Dan Zacchei / Joe Germani
dzacchei@longacresquare.com / jgermani@longacresquare.com
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024